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Abstract
Purpose: Needle track seeding in the local treatment of hepatocellular carcinoma (HCC) is not yet evaluated for 
catheter-based high-dose-rate brachytherapy (HDR-BT), a novel local ablative technique.
Material and methods: We report a retrospective analysis of 100 patients treated on 233 HCC lesions by HDR-BT 
(using 588 catheters in total). No needle or catheter track irradiation was used. Minimum required follow-up with im-
aging was 6 months. In case of suspected needle track seeding (intra- and/or extrahepatic) in follow-up, image fusion 
of follow-up CT/MRI with 3D irradiation plan was used to verify the location of a new tumor deposit within the path 
of a brachytherapy catheter at the time of treatment.
Results: We identified 9 needle track metastases, corresponding to a catheter-based risk of 1.5% for any location 
of occurrence. A total of 7 metastases were located within the liver (catheter-based risk, 1.2%), and 2 metastases were 
located extrahepatic (catheter-based risk, 0.3%). Eight out of 9 needle track metastases were successfully treated by 
further HDR-BT.
Conclusions: The risk for needle track seeding after interstitial HDR-BT of HCC is comparable to previous reports 
of percutaneous biopsies and radiofrequency ablation (RFA), especially in case of extrahepatic needle track metastases. 
To compensate for the risk of seeding, a track irradiation technique similar to track ablation in RFA should be imple-
mented in clinical routine.
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Purpose
Hepatocellular carcinoma (HCC) is a primary liver tu-
mor most often found in patients with liver cirrhosis and/
or viral hepatitis. Its incidence has increased over the last 
years worldwide [1]. Beneath surgical resection, local abla-
tive (e.g., radiofrequency ablation – RFA, microwave abla-
tion – MWA) and loco-regional (e.g., transarterial chemo-
embolization – TACE) treatments are favored for early to 
intermediate stage of HCC. However, these treatments 
may not be suitable for every patient due to technical re-
strictions [2,3,4]. Thermal ablation techniques have their 
limitations, especially in location close to vulnerable struc-
tures (e.g., bile ducts) and lesion size of 3.5 to 4 cm, while 
loco-regional techniques require sufficient, vascular access 
for the application of embolic agents, showing lack in local 
control if tumor nodules exceed a size of 5 to 7 cm [5,6]. 
Thus, computed tomography (CT)-guided high-dose-rate 
brachytherapy (HDR-BT) as a form of catheter-based ra-
diotherapy is a promising treatment option for tumors 
not accessible for thermal ablation techniques as well as 
an alternative to TACE. By inserting an Iridium 192 source 
through percutaneously applied catheters, interstitial 
brachytherapy has no technical restrictions in lesion size 
to deliver potentially ablative doses, and can be employed 
close to central structures [7,8]. In a series of studies, the 
safety and effectiveness of HDR-BT has already been 
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demonstrated, suggesting a potential as a bridging ther-
apy to liver transplantation in addition to radiofrequency 
ablation or transarterial chemoembolization [9].
The risk of spreading malignant cells during diag-
nostic and therapeutic methods have been reported for 
liver biopsy and thermal ablation with heterogeneous re-
sults, also varying by the utility of needle track ablation 
[10,11,12,13]. As the catheter placement for HDR-BT com-
prises an initial puncture (including possible corrections 
of the needle position) and insertion of catheter sheets in 
Seldinger’s technique, a corresponding risk of dislocating 
tumor cells through manipulation should be assumed.
The risk of needle track seeding after HDR brachyther-
apy, particularly in case of the potential utility as a bridg-
ing treatment for liver transplantation in early stage 
HCC, should be further investigated. On the other side, 
patients with larger tumor volumes in intermediate stage 
of the disease might have an increased risk for needle 
track seeding, as more catheter placements are required 
for a sufficient dose distribution [14]. In this retrospec-
tive study, we report needle track seeding after HDR 
brachytherapy in a series of 100 patients, with a total of 
588 catheter placements for local ablation of 233 HCC le-
sions. No catheter or needle track irradiation had been 
used in these patients. 
Material and methods
Eligibility criteria and patient cohort
We retrospectively analyzed patients who underwent 
interstitial HDR brachytherapy for HCC between 2006 
and 2012. All lesions were previously proven either by 
core needle biopsy or by matching the non-invasive cri-
teria of HCC in CT or magnetic resonance imaging (MRI) 
[15], according to the Clinical Practice Guidelines of the 
European Association for the Study of the Liver (EASL) 
released in 2012 [16].
100 patients (83 males, 17 females), with 233 HCC 
nodules and a total of 588 catheter placements met the in-
clusion criteria (see section follow-up). The average age at 
the time of intervention was 68 ± 8.1 years (44-82 years). 
Nearly all patients had an underlying liver cirrhosis 
(n = 98), mainly caused by alcohol consumption (n = 28) 
or viral hepatitis (n = 22). Infrequent causes of cirrhosis 
were non-alcoholic steatohepatitis (n = 8) and hemochro-
matosis (n = 2). In all other cases, the etiology of cirrhosis 
was cryptogenic (n = 38).
Only a minority of patients presented with extrahe-
patic disease including lymphatic (n = 5) or distant metas-
tases (n = 5). A summary of patient and treatment charac-
teristics is presented in Table 1.
Table 1. Patient and treatment characteristics and analysis on influencing factors for needle track seeding 
Variable % (N) or mean ± SD Patient-based p Lesion-based p Catheter-based p
Male/female 83% (83)/17% (17) 0.66 0.49 0.33
Age (years) 68.0 ± 8.1 0.26 0.21 0.37
Liver cirrhosis 98% (98/100)
hemochromatosis 2% (2/98) 1.0
viral hepatitis 22% (22/98) 1.0
ASH 29% (28/98) 0.99
NASH 8% (8/98) 0.99
other 39% (38/98)
HCC grading 62% (62/100) 0.54 0.23 0.3
well 39% (24/62)
moderate 55% (34/62)
poor 6% (4/62)
Concomitant sorafenib treatment 22% (22/78) 0.6 0.96 0.62
Pseudo-capsular HCC 8% (18/233) 0.98
Lesion size (cm) 3.3 ± 2.6 0.2 0.78 0.09
Ablation dose (Gy) 16.5 ± 11.6 0.65 0.7 0.59
Overpenetration (per catheter) 9% (53/588) 0.23 0.69
Catheter insertion lengths (cm)
/patient 74.8 ± 57.4 0.94
/lesion 32.1 ± 37.4 0.78
/catheter 12.7 ± 31.2 0.75
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HDR brachytherapy technique
In order to place an Iridium 192 source directly in 
the HCC lesions, irradiation catheters must be inserted 
into the tumor. The access for a soft catheter is accom-
plished by a percutaneous puncture with an 18 Ga coax-
ial needle under image guidance (CT or open MRI flu-
oroscopy) and subsequent insertion of an angiographic 
catheter sheet in Seldinger’s technique. The irradiation 
catheter is then placed inside the catheter sheath and 
fixed by a single suture. For planning purposes, di-
agnostic imaging (e.g., contrast enhanced CT) is per-
formed after complete catheter placement. Afterwards, 
a three-dimensional treatment plan is generated based 
on diagnostic imaging data acquired following catheter 
placement. Generally, the preferred surrounding dose 
for HCC is 15 Gy. After successful delivery of the de-
sired dose in a single fraction, the catheters and sheaths 
are removed leaving absorbable gelatin sponge in the 
track. Concomitant conscious sedation is achieved by 
individual administration of fentanyl and midazolam. 
A further description of irradiation technique and con-
comitant treatment is presented elsewhere [17].
Follow-up
All eligible patients required a follow-up consisting 
of CT or MRI at least 3 and 6 months after therapy, with 
a dynamic contrast-enhanced scan protocol including 
arterial, portal venous, and late venous phase. Any new 
intrahepatic lesion with a diameter of at least 1 cm and 
arterial enhancement with venous wash out was defined 
as an intrahepatic recurrence of HCC, while clear tumor 
growth outside the liver was sufficient for the definition 
of extrahepatic lesions [16]. 
Subsequent therapies in the follow-up period includ-
ed sorafenib (n = 22), transarterial chemoembolization 
(n = 18), Y90 radioembolization (n = 4), and radiofrequen-
cy ablation (n = 4).
Imaging analysis
We determined the primary tumor size, number and 
location of metastases, the total length of each catheter 
from the skin to the tip as well as ‘over-penetration’ of the 
tip beyond the HCC lesion. 
As a first step, the available image data sets were eval-
uated for the probability of needle tract seeding accord-
ing to the following definitions: 1) Temporal causality: 
needle track seeding should be diagnosed after therapy 
within a reasonable timeframe of 2 years; 2) Local causal-
ity: needle tract seeding had to be situated around a prior 
catheter track within a margin of 1 cm.
In a second step, the suspected needle track metas-
tases had to be objectively verified. Amira® 3.x was ap-
plied for the fusion of CT/MRI and irradiation treatment 
plans. Overlay images were generated to determine the 
exact position of the suspected metastases in relation to 
the prior catheter location. 
As a novel approach, we assessed both, extrahepatic 
and intrahepatic seeding. An example of an image fusion 
data set is provided in Figure 1.
Fig. 1. Image fusion data set: peri-interventional CT show-
ing HDR brachytherapy catheter (arrow, A), follow-up 
MRI suspecting a needle track lesion (arrow, B), axial 
image fusion of follow-up MRI and planning CT of HDR 
brachytherapy confirming the origin of the new lesion 
within the former path of the brachytherapy catheter (ar-
row, C)
A
B
C
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Statistical analysis
We collected technical data of the irradiation plan and 
documented possible risk factors such as patient demo-
graphics, histological grading, and imaging features. 
The statistical analysis of the data was conducted by 
using the statistical software SPSS® and SAS®. Differ-
ences between variables were examined using Student’s 
t-test for metric variables and Chi-Square test for frequen-
cies. The survival analysis was performed according to 
Kaplan-Meier method, the statistical significance was de-
termined using log-rank test. The influence of potential 
risk factors on the occurrence of needle track metastases 
was calculated using a generalized linear mixed model. 
All tests were performed two-sided, a p-value of p ≤ 0.05 
was considered statistically significant.
Results
Patient and treatment characteristics
In our cohort of 100 patients, a total of 233 HCC le-
sions were treated. In 62 patients, histological reports 
were available with 38.7% (n = 24) being well differenti-
ated, 54.8% (n = 34) being moderately differentiated, and 
6.5% (n = 4) being poorly differentiated tumors. Pseu-
do-capsular HCC were present in 18 out of 233 lesions 
(7.7%). 22 patients (22%) received concomitant therapy 
with sorafenib.
In all patients, thermal ablation was technically not 
favorable related to either tumor size (exceeding 3 cm) 
or tumor location (proximity to liver hilum or adjacent 
gastrointestinal structures) of at least one lesion. 
The median follow-up was 15.7 months (range, 6-70.2 
months). Within the observation period, 67 patients de-
veloped a tumor progression with a median progres-
sion-free survival of 7.0 months. Median overall survival 
of all patients was 20.0 months. A summary of patient 
and treatment characteristics is presented in Table 1.
Catheter-based analysis 
A total number of 588 catheters were placed within 
100 patients. The mean insertion length of a single cathe-
ter was 12.7 ± 31.2 cm (range, 5.7-25.4 cm). Four catheters 
were too remote in relation to the target lesion and were 
not used for irradiation (0.7%). However, these lesions 
were treated in the same session with more precisely 
placed catheters. A total of nine needle track metastases 
were identified yielding an incidence of 1.5% per cathe-
ter placement. Seven out of nine seeding metastases were 
located within the liver (catheter-based risk for intrahe-
patic seeding, 1.2%). Two metastases occurred within the 
peritoneal cavity in the location of a former catheter path 
(catheter-based risk for extrahepatic seeding, 0.3%). 
Lesion-based analysis 
A total of 233 HCC lesions were treated. The mean di-
ameter of HCC nodule was 3.3 ± 2.6 cm (range, 1.0-16.6 cm) 
requiring a mean number of 2.6 catheters per lesion to 
ensure a sufficient dose application. The mean applied 
radiation dose at the tumor rim was 16.5 ± 11.6 Gy. 
The mean sum of in-body catheter length per lesion was 
32.1 ± 37.4 cm (range, 5.9-247.0 cm). Over-penetration of 
HCC nodule was found in 53 cases (9.0%), with a mean 
over-penetration length of 1.2 cm (range, 0.1-2.8 cm). 
The cumulative frequency of needle track metastases per 
treated tumor was 3.9% (intrahepatic location, 3.0%; ex-
trahepatic location, 0.9%). 
Patients-based analysis 
In our cohort of 100 patients, an average number of 
5.9 catheters were placed per patient leading to a mean 
total in-body catheter length of 74.8 ± 57.3 cm (range, 8.6-
288.8 cm). Imaging analysis revealed needle track metas-
tases in 9 patients. The mean time of occurrence of needle 
track seeding was 5.5 months (range, 4.8-6.2 months). 
Risk assessment 
Needle track seeding occurred in a median time inter-
val of 5.5 months (range, 4.8-6.2 months). No increased 
risk was found for the tumor grading, age, and sex. 
In a catheter-based analysis, we found more frequent 
seeding in smaller HCC lesions (p = 0.09). Liver cirrhosis 
and underlying etiology had no significant influence on 
the development of needle track seeding; the same was 
seen for pseudo-capsular HCC. Treatment-related pa-
rameters such as catheter insertion lengths, over-penetra-
tion of the lesion (i.e., with the possibility of dislocating 
tumor cells beyond the lesions into the liver parenchy-
ma), and applied dose as well as concomitant treatment 
with sorafenib, demonstrated no significant influence. 
Of note, 8 out of 9 seeding metastases were success-
fully treated by further HDR-BT directly after their oc-
currence. In one case, needle track metastasis occurred 
parallel to systemic progression at other sites and needed 
systemic therapy with sorafenib. 
Median overall survival was 25.0 months in patients 
with needle track vs. 20.0 months in patients without 
(p = 0.86, log-rank test). The overall results of the risk fac-
tor analysis are included in Table 1. 
Discussion 
We were able to calculate the risk for tumor seeding 
after local ablation of HCC by catheter-based radiothera-
py for both intrahepatic and extrahepatic locations, with 
an analysis of catheter-, lesion-, and patient adjusted fre-
quencies. No track irradiation had been used in these pa-
tients. 
Needle track seeding in local ablation 
Needle track seeding in HCC is known to occur after 
diagnostic biopsies and local ablative procedures such 
as radiofrequency or microwave ablation. Stigliano et al. 
reported a meta-analysis of diagnostic and therapeutic 
interventions in 2007, with an overall frequency of 1.27% 
after liver biopsy and/or local ablation with extrahepatic 
needle track metastases [11].
Initial reports of seeding in up to 12.5% of patients 
after RFA illustrated the demand of track ablation tech-
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niques [18]. Similarly, recent reports after RFA and MWA 
using track ablation depict low seeding rate of 0.61% to 
1.6% [13,19]. However, all these studies have focused on 
extrahepatic seeding only; intrahepatic seeding was not 
evaluated to differentiate tumors seeding from de novo 
HCC due to technical limitations. 
Our recent study identified a cumulative (extrahe-
patic and intrahepatic) catheter-based risk for seeding of 
1.5% (without track ablation technique), which is compa-
rable to reported seeding risk after thermal ablation using 
track ablation or even lower, considering that literature 
focusses on extrahepatic seeding only. 
Due to the need of multiple catheters in larger HCC 
lesions (mean lesion diameter in our cohort: 3.3 ± 2.6 cm; 
range, 1.0-16.6 cm), the cumulative lesion-based seeding 
risk is as high as 3.9%. Theoretically, the seeding risk is 
still comparable to thermal ablation techniques, consid-
ering the need for multiple probes/multiple positions 
and in RFA or MWA ablation for the treatment of larger 
tumors. 
Extrahepatic seeding 
As stated above, our data indicates that the risk for 
extrahepatic seeding (0.2% per catheter) after HDR 
brachytherapy is comparable or even lower than after 
thermal-based ablative techniques (0.61-1.6%). Further-
more, our data supports findings previously published 
by Denecke et al. who utilized HDR brachytherapy in the 
pre-transplant setting and found no extrahepatic recur-
rence due to seeding in their smaller group of patients 
undergoing subsequent liver transplantation [9]. In fact, 
only a minority of seeding metastases occurred outside 
the liver in our cohort (0.2% per catheter). Assuming a tu-
mor size and tumor number within transplant criteria for 
HCC, the lesion-based and patient-based risk should be 
equal or only slightly increased in those patients as com-
pared to the catheter-based risk supporting the findings 
of Denecke et al. Both, the work of Denecke et al. and our 
results support the use of HDR brachytherapy as bridg-
ing for transplant, at least in tumors with an unfavorable 
location for RFA or TACE. 
In case of larger or multilocular HCC outside trans-
plant criteria, multiple catheter placements in HDR 
brachytherapy are usually necessary, resulting in a high-
er seeding rate (e.g., 0.9% in lesion-based analysis). The-
oretically, several needle positions would have been re-
quired for a complex thermal ablation in those patients. 
Thus, the cumulative risk (i.e., lesion- and catheter-based 
risk) for track seeding seen in our study can be assumed 
to be comparable to a cumulative risk resulting from mul-
tiple ablation positions in RFA/MWA [11,20,21].
Intrahepatic seeding
Unfortunately, many studies still neglect the possibil-
ity of intrahepatic seeding, probably as the differentiation 
between intrahepatic seeding metastases and tumor pro-
gression is difficult [12]. We applied a novel approach of 
image fusion for the identification of intrahepatic seeding, 
leading to the confident identification of lesions, which 
most likely derive from track seeding. All these lesions 
are omitted by the extrahepatic definition of seeding in 
most studies. In fact, intrahepatic needle track metastases 
were more frequent as compared to extrahepatic needle 
track metastases with a catheter-based risk of 1.3%. This 
is easily explainable, since the penetration depth within 
the liver parenchyma is usually longer than the thickness 
of the abdominal wall. 
The higher rate of intrahepatic seeding as compared 
to extrahepatic seeding in our analysis, along with the fo-
cus on extrahepatic-only seedings in literature, suggests 
that seeding (intrahepatic plus extrahepatic) after thermal 
ablation or biopsy might be more frequent, but data to 
further elucidate that matter is not available. However, 
this might pose a clinical impact for treatment decision 
making and should be a subject for further investigation. 
Furthermore, techniques to decrease the seeding rate after 
HDR brachytherapy were not applied in the study popu-
lation. As a consequence of our analysis, we established 
a procedure similar to needle track ablation by radiation 
of the path of the catheter during the withdrawal of the 
Iridium 192 source, with a mean dose of 10 Gy in up to 
2-3 mm depth. Taking RFA and MWA as an example, the 
introduction of track ablation techniques resulted in dras-
tically lower rate of (extrahepatic) seeding (from 12.5% 
to 0.61-1.6%; see above), indicating a significant influence 
of track ablations techniques to control tumor seeding in 
local ablations of HCC. We believe that this applies also 
to HDR brachytherapy. 
Beside this assumed influencing factor on track seed-
ing, none of the evaluated variables within the study re-
vealed a significant influence on the rate of track seed-
ing on a catheter-, lesion-, and patient-based analysis, as 
these were in particular sex, age, etiology of liver disease, 
grading of the HCC, evidence of a tumor pseudo-cap-
sular, size of the targeted lesion, in situ catheter length, 
over-penetration of the targeted lesion, ablation dose, 
and concomitant systemic treatment. Only the size of tar-
geted lesion showed a tendency to significantly influence 
track seeding (in the patient-based analysis, p = 0.09), 
with a higher rate of track seeding in smaller lesions. It 
can be hypothesized that more manipulations (i.e., nee-
dle passes to enable a sufficient catheter placement) are 
needed in smaller lesions. Quantitative or semi-quanti-
tative information on needle manipulations during the 
intervention were not available in this study making fur-
ther clarification of this hypothesis impossible. However, 
since this finding was only evident on a patient-based 
analysis but not on a lesion- or catheter-based analysis, 
stochastic effects are the most probable cause.
Limitations 
The limitations of this analysis are those inherent to 
a retrospective analysis. Although study format was ret-
rospective, the data (clinical data, treatment-related data) 
were obtained from a prospectively managed database, 
in which all patients who undergo a local or loco-region-
al treatment at our department are electronically filed 
using standardized reporting forms for treatment and 
follow-up visits. Additionally, treated patient undergo 
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a standardized follow-up including imaging (at our insti-
tution) every three months, which diminishes a possible 
bias derived from inconsistent image follow-up intervals 
and inconsistent imaging protocols. However, a patient 
selection bias cannot be ruled out. 
As pointed out in the section above, we were not able 
to evaluate systematically the incidence of needle manip-
ulations during the interventions, which could have an 
influence on the risk of track seeding, since the number 
of possible tumors passes increases. However, misplace-
ments of the needle during the intervention usually occur 
outside the tumor (i.e., in the liver parenchyma without 
risk for seeding), a believed position within the tumor (al-
though position might not be perfect for treatment) entail 
the exchange to the brachytherapy catheter by standard 
operating procedure in order to prevent seeding. Thus, 
we believe that the possible influence of needle manip-
ulations during the interventions is too small to neglect. 
Finally, the differentiation between iatrogenic track 
seeding and de novo HCC is still a challenge that might 
influence the analysis. Since all possible track seeding 
metastases were verified in their origin by precise image 
registration of the follow-up imaging with the final im-
aging after placement of the brachytherapy catheters, we 
can rule out an underestimation of the frequency of treat-
ment-associated track seeding. Only a risk for an over-
estimation of the frequency of new metastases related to 
the previously performed local ablation is possible but is 
regarded as acceptable from a clinical and scientific per-
spective. 
Conclusions
The technique of percutaneous catheter placement for 
HDR brachytherapy in HCC is generally not associated 
with an elevated risk of needle track metastases as com-
pared to biopsy or RFA/MWA, especially in extrahepatic 
seeding. In fact, data indicates a lower risk for track me-
tastases after HDR brachytherapy as compared to biopsy 
and thermal-based ablation techniques, although HDR 
brachytherapy was conducted without a track ablation 
technique in this study. 
To further reduce the risk of seeding along the cathe-
ter path, track irradiation in HDR brachytherapy should 
be implemented in daily practice. 
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